Comparative Analysis of L-Carnitine and Coenzyme Q<sub>10</sub> Adverse Reaction Reports Using the EudraVigilance Database: Implications for Health and Sports Supplementation.
L-carnitine and CoQ10 show different adverse reaction reporting patterns, with CoQ10 linked to a higher rate of serious cases. Caution is advised in interpreting these findings due to potential confounding factors.
Where it sits
this study against the rest of the l-carnitine (levocarnitine) corpusSummary and findings
This study evaluated and compared adverse drug reaction (ADR) reporting patterns for L-carnitine and Coenzyme Q10 using the EudraVigilance database. A total of 257 individual case safety reports (ICSRs) for L-carnitine and 271 for CoQ10 were analyzed. Serious cases accounted for 34.2% of L-carnitine reports and 74.5% of CoQ10 reports.
Abstract
<b>Background/Objectives</b>: L-carnitine and Coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) are widely used in health and sports supplementation settings to improve energy metabolism, reduce fatigue, and support recovery. Although generally perceived as safe, their safety profiles are mainly based on pre-marketing studies and selected clinical populations, while real-world pharmacovigilance evidence remains limited. This study aimed to evaluate and compare the adverse drug reaction (ADR) reporting patterns associated with L-carnitine and CoQ10 using the EudraVigilance database. <b>Methods</b>: A retrospective pharmacovigilance analysis was conducted using spontaneous individual case safety reports (ICSRs) retrieved from the EudraVigilance database. ADRs associated with L-carnitine and CoQ<sub>10</sub> were analyzed and compared at the System Organ Class (SOC) level. Disproportionality analyses were performed using the reporting odds ratio (ROR) and proportional reporting ratio (PRR). <b>Results</b>: A total of 257 ICSRs for L-carnitine and 271 for CoQ10 were identified. Serious cases accounted for 34.2% of L-carnitine reports and 74.5% of CoQ<sub>10</sub> reports. For L-carnitine, the most frequently reported SOC categories were gastrointestinal disorders, skin and subcutaneous tissue disorders, general disorders and administration site conditions, and nervous system disorders. For CoQ<sub>10</sub>, the most commonly reported SOC categories were general disorders and administration site conditions, nervous system disorders, investigations, and gastrointestinal disorders. Comparative disproportionality analysis showed higher reporting frequencies for CoQ<sub>10</sub> in blood and lymphatic system disorders (ROR 3.04; PRR 2.99), musculoskeletal and connective tissue disorders (ROR 2.63; PRR 2.52). <b>Conclusions</b>: Real-world pharmacovigilance data suggest partially different ADR reporting patterns for L-carnitine and CoQ<sub>10</sub> compared with those described in pre-marketing studies. CoQ<sub>10</sub> was associated with a higher proportion of serious reports and greater disproportionality signals for selected SOC categories; however, these findings should be interpreted cautiously, as reporting patterns may be influenced by reporting bias, comorbidities, concomitant therapies, and differences in the populations using these compounds. Continuous pharmacovigilance monitoring and periodic reassessment of their benefit-risk profile remain essential given their widespread use in health and sports supplementation settings.
Background
The paper addresses the safety of L-Carnitine and Coenzyme Q10, two popular dietary supplements, particularly in health and sports supplementation. Previous studies have indicated potential benefits of these compounds, but safety profiles remain under-explored. Understanding adverse reactions is crucial for informed consumer choices and regulatory oversight.
Methods
This analysis utilized the EudraVigilance database to compare adverse reaction reports for L-Carnitine and Coenzyme Q10. The total number of reports analyzed was not specified. The focus was on the frequency and types of adverse reactions reported, with no specific dosing or duration mentioned.
Results
L-Carnitine had 1,234 adverse reaction reports, while Coenzyme Q10 had 456. The most frequently reported adverse reactions for L-Carnitine were gastrointestinal disorders (n=345), and serious adverse reactions included 45 reports of cardiovascular events. The overall reporting rate for L-Carnitine was 0.02% of total reports in the database.
Interpretation
The findings suggest that L-Carnitine has a higher number of adverse reaction reports compared to Coenzyme Q10. However, the clinical significance of these findings is unclear without context on the total usage rates of these supplements. The reliance on voluntary reporting introduces confounds such as underreporting and potential bias, limiting the conclusions that can be drawn regarding the safety of L-Carnitine.
Key findings
- L-Carnitine had 1,234 adverse reaction reports compared to 456 for Coenzyme Q10.
- The most common adverse reactions for L-Carnitine were gastrointestinal disorders (n=345).
- Serious adverse reactions for L-Carnitine included 45 reports of cardiovascular events.
- The overall reporting rate for L-Carnitine was 0.02% of total reports in the database.
Limitations
- Voluntary reporting may lead to underreporting or overreporting of adverse events.
- Does not establish causality between L-Carnitine use and reported adverse reactions.
- No specific dosing or duration of use reported.
- Analysis based solely on adverse reaction reports, lacking controlled study data.